The Sec61 translocon is a therapeutic vulnerability in Multiple Myeloma
A. Domenger, C. Choisy, L. Baron, V. Mayau, L. Deriano, B. Arnulf, J.-C. Bories, G. Dadaglio, C. Demangel
This study shows that targeting the Sec61 translocon with mycolactone enhances the effectiveness of bortezomib in killing multiple myeloma cells and reduces toxicity.
bioRxiv · Sep 5, 2021Cancer Biology